Achieve Life Sciences, Inc.

NasdaqCM ACHV

Achieve Life Sciences, Inc. Capital Expenditure for the year ending December 31, 2023: USD -21.00 K

Achieve Life Sciences, Inc. Capital Expenditure is USD -21.00 K for the year ending December 31, 2023, a 0.00% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Achieve Life Sciences, Inc. Capital Expenditure for the year ending December 31, 2022 was USD 0.00, a 100.00% change year over year.
Achieve Life Sciences, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -17.00 K, a 0.00% change year over year.
Achieve Life Sciences, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -17.00 K, a 67.92% change year over year.
Achieve Life Sciences, Inc. Capital Expenditure for the year ending December 31, 2019 was USD -53.00 K, a -15.22% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: ACHV

Achieve Life Sciences, Inc.

CEO	Dr. Richard A. B. Stewart
IPO Date	Oct. 12, 1995
Location	Canada
Headquarters	1040 West Georgia Street
Employees	22
Sector	Consumers Staples
Industries Tobacco Biotechnology Drugstores & Retail Pharmacies Pharmaceuticals

Description

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Key trends

Past 5 years